BIVI Quote, Financials, Valuation and Earnings

Axsome Therapeutics has a net margin of -- compared to BioVie's net margin of -48.92%. BioVie's return on equity of -- beat Axsome Therapeutics's return on equity of -309.19%.

BioVie has a consensus price target of $5.50, signalling upside risk potential of 391.07%. On the other hand Axsome Therapeutics has an analysts' consensus of $176.35 which suggests that it could grow by 63.65%. Given that BioVie has higher upside potential than Axsome Therapeutics, analysts believe BioVie is more attractive than Axsome Therapeutics.

BioVie has a beta of 1.180, which suggesting that the stock is 18.039% more volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.356%.

BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.

BioVie quarterly revenues are --, which are smaller than Axsome Therapeutics quarterly revenues of $121.5M. BioVie's net income of -$7.1M is higher than Axsome Therapeutics's net income of -$59.4M. Notably, BioVie's price-to-earnings ratio is -- while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus 12.04x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to BioVie's net margin of -49.65%. BioVie's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

BioVie has a consensus price target of $5.50, signalling upside risk potential of 391.07%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 49.07%. Given that BioVie has higher upside potential than NovaBay Pharmaceuticals, analysts believe BioVie is more attractive than NovaBay Pharmaceuticals.

BioVie has a beta of 1.180, which suggesting that the stock is 18.039% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

BioVie quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. BioVie's net income of -$7.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, BioVie's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Tonix Pharmaceuticals Holding has a net margin of -- compared to BioVie's net margin of -856.24%. BioVie's return on equity of -- beat Tonix Pharmaceuticals Holding's return on equity of -138.47%.

BioVie has a consensus price target of $5.50, signalling upside risk potential of 391.07%. On the other hand Tonix Pharmaceuticals Holding has an analysts' consensus of $60.00 which suggests that it could grow by 216.79%. Given that BioVie has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe BioVie is more attractive than Tonix Pharmaceuticals Holding.

BioVie has a beta of 1.180, which suggesting that the stock is 18.039% more volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding has a beta of 1.627, suggesting its more volatile than the S&P 500 by 62.658%.

BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding pays out -- of its earnings as a dividend.

BioVie quarterly revenues are --, which are smaller than Tonix Pharmaceuticals Holding quarterly revenues of $2.6M. BioVie's net income of -$7.1M is higher than Tonix Pharmaceuticals Holding's net income of -$22.1M. Notably, BioVie's price-to-earnings ratio is -- while Tonix Pharmaceuticals Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus 2.38x for Tonix Pharmaceuticals Holding. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to BioVie's net margin of --. BioVie's return on equity of -- beat Theriva Biologics's return on equity of --.

BioVie has a consensus price target of $5.50, signalling upside risk potential of 391.07%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 832.84%. Given that Theriva Biologics has higher upside potential than BioVie, analysts believe Theriva Biologics is more attractive than BioVie.

BioVie has a beta of 1.180, which suggesting that the stock is 18.039% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

BioVie quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. BioVie's net income of -$7.1M is lower than Theriva Biologics's net income of -$4.4M. Notably, BioVie's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.